24/7
Buzz
Startups
VC
@work
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
DataTech
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Ajovy
Tags search
HOME
24/7
buzz
STARTUPS
VC
Tech@work
Innovation
OPINIONS
EVENTS
ABOUT
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
15:37
Full list of Israeli high-tech funding rounds in 2023
15:00
Fintech startup Wisor AI raises $8 million in Seed for freight booking software solution
13:17
Japan's ORIX invests in theDOCK’s Navigator II maritime and supply chain fund
12:33
$400 million lawsuit reveals how Eytan Stibbe allegedly scammed his ex-partners in Africa
More stories
Buzz
Most popular
Daily
Weekly
1
Quiet Hiring: The new trend in talent management
2
EU would view Israel “in the same category as China” if judicial reforms go through
3
Cybersecurity company Cyren on verge of shut down after laying off entire workforce
4
“AI is being used in almost every medical field"
5
Billionaire Steve Cohen leads $27.5 million investment in MediWound
More news
Ajovy
7 stories about Ajovy
Teva Receives FDA Approval for Migraine Autoinjector
29.01.20
|
Sophie Shulman
Teva’s anti-migraine injection was approved in late 2018 but struggled to establish a market share due to both Amgen and Eli Lilly offering a similar drug with an autoinjector
Teva’s Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing
17.11.19
|
Navit Zomer
The Israeli drugmaker’s manufacturing facility in Kfar Saba, already experienced with manufacturing cash cow Copaxone, will oversee the process of filling the syringes with the biological drug and also conduct quality control tests
Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself
11.11.19
|
Uri Tal-Tene
With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
Teva Discontinues Development of Cluster Headache Drug
24.04.19
|
Tzally Greenberg
Under Teva’s brand name Ajovy, fremanezumab has already been approved in the U.S. and Europe as a preventative migraine treatment
Market Indifferent to European Approval of Teva's Migraine Drug
02.04.19
|
Lilach Baumer
Teva's injection, one of three similar migraine drugs already approved in the U.S., is the third to receive European approval after Amgen Inc. and Novartis AG and Eli Lilly
CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports
27.01.19
|
Lilach Baumer
In October, American prescription benefits management company Express Scripts added Amgen and Eli Lilly’s drugs to its coverage but excluded Teva
Teva Shares Rise Following FDA Approval of Migraine Drug
16.09.18
|
Dror Reich
Teva’s new migraine drug is forecasted to bring in $500 million in sales annually